By Cecilia Butini

 

Novartis AG said late Wednesday that the U.S. Food and Drug Administration has given its prostate-cancer treatment, Pluvicto, the green light, and it is now expected to become available within weeks.

The Swiss pharma company said that Pluvicto works against a certain type of advanced prostate cancer.

The FDA approval is based on the result of a Phase 3 trial which showed that patients treated with the drug, plus the standard available treatment, had a 38% reduction in the risk of death, Novartis said.

 

Write to Cecilia Butini at cecilia.butini@wsj.com

 

(END) Dow Jones Newswires

March 24, 2022 02:44 ET (06:44 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024 Haga Click aquí para más Gráficas Novartis.
Novartis (NYSE:NVS)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024 Haga Click aquí para más Gráficas Novartis.